Albumedix buys Eleven's half-life boosting albumin assets

By Gareth Macdonald

- Last updated on GMT

Novozymes buys Eleven's albumin assets
Novozymes buys Eleven's albumin assets
Novozymes’ albumin technologies division Albumedix has bought Eleven Biotherapeutics’ half-life extension assets.

The deal – which completed in December – has added Eleven’s recombinant albumin technologies to Albumedix offering, which includes the half-life boosting Veltis system  – previously known as Recombumin Flex​ – the is licensed by UK drugmaker GSK​. 

Eleven’s technology – known as Supermin - was created using its protein engineering system – AMP-Rx – which the firm claims speeds up the development process. 

Albumedix paid Eleven an upfront fee and will pay commercialization royalties

Peter Rosholm, Albumedix CEO, said: “The acquisition of Eleven's exciting albumin platform, which will be incorporated within our proven Veltis ​technology portfolio, will strengthen our existing offering​.”

Albumin plan 

Novozymes launched Albumedix this month​ explaining that the wholly-owned subsidiary will make proteins used to stabilize and extend the half-lives of drugs and vaccines.

In addition to GSK, Albumedix customers include US drugmaker Merck & Co which has used its technologies in vaccines since 2006​ and Serendex Pharmaceutical, which recently began a Phase I trial​ of a lung disease treatment that is stabilized with Recombumin.

However, the Danish firm also plans to develop its drugs according to Rosholm.

He told Biophamra-reporter.com that: “Albumedix’s strategy is to develop a small pipeline of drugs that uses our technologies to maximise return on our investment​.”

Rosholm did not disclose any specific targets but did say the products are likely to be biobetters.

Biobetters are tweaked versions of existing biopharmaceuticals that improve on the original by having, for example, longer half-lives that allow for reduced dosing.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Webinars

Headlines